Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
IceCure Medical’s ChoICE post-market study is evaluating the ProSense cryoablation system as a minimally invasive treatment option for eligible older patients with low-risk, early-stage breast cancer. Representative image.
Medical Devices & Diagnostics

What will IceCure Medical’s ChoICE study reveal about ProSense breast cancer cryoablation?

IceCure Medical launches the ChoICE post-market study at West Cancer Center, testing ProSense adoption and five-year outcomes in breast cancer.

Read More
Representative image: A clinician applies a microneedle skin patch as Medicus Pharma $MDCX advances its SkinJect treatment into an FDA-cleared Phase 2b study for basal cell carcinomas in Gorlin syndrome.
Pharma & Biotech

FDA clears Medicus Pharma SkinJect registrational study in Gorlin syndrome

FDA clears Medicus Pharma’s Phase 2b SkinJect study in Gorlin syndrome with biopsy-confirmed endpoints and two-year follow-up.

Read More
Representative image: A neurological research team reviews brain scans and antisense therapy data as CAMP4 Therapeutics $CAMP prepares to begin the first human CMP-002 trial for SYNGAP1-related disorder.
Pharma & Biotech

CAMP4 clears Australian hurdle for first human CMP-002 study in SYNGAP1 disorder

CAMP4 gains Australian clearance for a Phase 1/2 CMP-002 trial targeting the genetic cause of SYNGAP1-related disorder.

Read More
Massive Bio expands Latin America oncology strategy through GELL research partnership
Pharma & Biotech

Can Massive Bio and GELL turn Latin America’s lymphoma research gaps into an AI-powered clinical trial advantage?

Massive Bio and GELL unite on oncology research, education and AI, but execution will determine whether the alliance expands trial access.

Read More
Huonslab’s new patent targets subcutaneous antibody-drug conjugate formulations using its HyDIFFUZE platform, highlighting the growing race to make complex oncology therapies easier and faster to administer. Representative image.
Pharma & Biotech

Can Huonslab crack oncology’s next drug-delivery problem? New patent targets injectable ADCs

Huonslab’s HyDIFFUZE patent targets subcutaneous ADC formulations, but preclinical evidence and clinical translation remain the real test.

Read More
Dopl Technologies’ $6.3 million seed funding is set to advance the Traverse telerobotic ultrasound platform toward FDA clearance, as remote robotic imaging gains attention for expanding diagnostic access in underserved hospitals. Representative image.
Medical Devices & Diagnostics

Can Dopl Technologies turn a $6.3m seed round into the remote ultrasound network rural hospitals need?

Dopl Technologies raises $6.3 million to fund FDA work for Traverse telerobotic ultrasound, but clinical validation and adoption remain key.

Read More
Precision BioSciences’ leadership reshuffle puts PBGENE-HBV and PBGENE-DMD clinical execution in focus as the gene-editing company approaches key 2026 milestones. Representative image.
Pharma & Biotech

Precision BioSciences prepares leadership team for PBGENE-HBV and PBGENE-DMD data milestones

Precision BioSciences reshapes leadership to support PBGENE-HBV and PBGENE-DMD as two gene-editing trials approach key 2026 milestones.

Read More
Digital critical care monitoring in a modern hospital setting, reflecting FIZE Medical’s European and UK commercial expansion after CE marking and UKCA certification for the FIZE kUO automated urine output system. Representative image.
Medical Devices & Diagnostics

FIZE Medical receives CE marking and UKCA certification for FIZE kUO

FIZE Medical’s CE and UKCA milestones open Europe and Great Britain to FIZE kUO, shifting attention to ICU adoption and clinical evidence.

Read More
Vasomune Therapeutics is positioning investigational Tie2 agonist Pegevongitide for potential use in vascular leak, severe trauma and CBRN-related medical emergencies ahead of its NATO NSPA presentation. Representative image.
Pharma & Biotech

Why Vasomune is taking its vascular leak drug to NATO before the clinical case is settled

Vasomune will present Pegevongitide at NATO’s CBRN forum, but clinical data and countermeasure readiness remain the decisive tests.

Read More
AbelZeta’s FDA-cleared registrational Phase II trial will evaluate the investigational dual-target CAR-T therapy C-CAR168 in patients with refractory lupus nephritis. Representative image.
Pharma & Biotech

Can AbelZeta turn a tiny lupus dataset into a registrational CAR-T breakthrough?

AbelZeta's FDA-cleared Phase II C-CAR168 trial tests whether dual-target CAR-T can deliver durable renal responses in refractory lupus nephritis.

Read More